Last updated: August 21, 2026
Ammonio methacrylate copolymer type B is a functional pharmaceutical excipient used primarily for sustained-release and water-insoluble film coatings. Its commercial benchmark is Evonik’s EUDRAGIT RS product family, including aqueous dispersion and organic-soluble grades. Demand is tied to oral modified-release medicines, generic reformulations, multiparticulate dosage forms, and lifecycle management rather than direct consumer prescribing.
The market has defensible technical demand but limited public financial transparency. Evonik does not separately disclose revenue, margin, or volume for EUDRAGIT or ammonio methacrylate copolymer type B. The most supportable financial view is therefore directional: stable to moderately growing demand, pricing influenced by specialty-excipient qualification, and revenue concentration among a small number of established suppliers.
What is ammonio methacrylate copolymer type B used for?
Ammonio methacrylate copolymer type B is a water-insoluble acrylic polymer that permits controlled diffusion of drug substances through a coating membrane. It is used in:
- Sustained-release tablets
- Extended-release capsules
- Pellets and multiparticulates
- Taste-masked granules
- Gastro-resistant or delayed-release systems when combined with other polymers
- Drug-layered beads and reservoir systems
- Combination coatings with water-soluble or enteric polymers
The polymer contains quaternary ammonium groups that create controlled permeability. Type B has lower ionic-group content than type A, producing a less permeable film. In the EUDRAGIT nomenclature, type A is generally associated with RL grades and type B with RS grades. EUDRAGIT RS polymers are designed for sustained drug release, while RL grades provide greater permeability and faster release under comparable coating conditions.[1]
The polymer is not an active pharmaceutical ingredient and does not create therapeutic exclusivity by itself. Its value lies in reproducible release control, manufacturing performance, regulatory history, and formulation know-how.
Which commercial products correspond to ammonio methacrylate copolymer type B?
The principal commercial reference is EUDRAGIT RS, manufactured and commercialized by Evonik. Products are available in different physical formats, including aqueous dispersions and dry powders.
| Compendial or functional category |
Common commercial reference |
Typical use |
| Ammonio methacrylate copolymer type B |
EUDRAGIT RS 30 D |
Aqueous sustained-release coating |
| Ammonio methacrylate copolymer type B |
EUDRAGIT RS PO |
Organic-soluble or dry-polymer processing |
| Ammonio methacrylate copolymer type A |
EUDRAGIT RL grades |
Higher permeability sustained-release coating |
| Polyvinyl acetate dispersion |
BASF Kollicoat SR 30 D |
Alternative sustained-release film former |
| Ethylcellulose dispersion |
Colorcon Surelease |
Alternative water-insoluble coating system |
EUDRAGIT RS 30 D is a 30% aqueous dispersion used for coating pharmaceutical particles and dosage forms. EUDRAGIT RS PO is a powder form used in processes that require dry blending, granulation, or organic-solvent application.[1]
Kollicoat SR 30 D and ethylcellulose systems compete at the formulation level, although they are not chemical equivalents. Selection depends on release profile, coating weight, solvent system, process equipment, mechanical properties, regulatory history, and compatibility with the drug substance.
How large is the ammonio methacrylate copolymer type B market?
A reliable standalone global market size is not publicly disclosed. Commercial market reports generally aggregate acrylic polymers with broader pharmaceutical excipients, film coatings, controlled-release materials, or oral drug-delivery excipients. Those categories are too broad to produce a defensible estimate for ammonio methacrylate copolymer type B alone.
The addressable market is best assessed through demand drivers:
- Oral modified-release products remain a major formulation category.
- Generic-drug manufacturers use controlled-release coatings to reproduce reference-product performance.
- Innovator companies use multiparticulate and extended-release technologies for lifecycle management.
- Contract development and manufacturing organizations increasingly perform formulation and coating work for third parties.
- Regulatory requirements favor excipients with established pharmaceutical use and documented quality systems.
The product is a specialty excipient rather than a commodity polymer. Its unit price is higher than that of basic pharmaceutical fillers, but total polymer consumption per product is limited by coating weight and batch scale. Revenue growth therefore depends more on the number of qualified products and production volumes than on broad pharmaceutical-unit growth.
What is driving demand for ammonio methacrylate copolymer type B?
Growth in modified-release generics
Modified-release generics require more formulation development than immediate-release products. Developers must match dissolution profiles, control dose dumping, manage food effects, and demonstrate bioequivalence. Ammonio methacrylate copolymer type B is useful in these programs because coating permeability can be adjusted through polymer blends, coating thickness, plasticizer selection, curing, and processing conditions.
The polymer can reduce development time when the developer has prior experience with the grade and an established analytical method. That creates repeat purchasing after a product enters commercial production.
Expansion of multiparticulate dosage forms
Pellets and coated beads allow developers to distribute drug across multiple units, combine release populations, and reduce the risk of localized dose delivery. Ammonio methacrylate copolymer type B is widely suited to these systems because it can form controlled-release membranes around drug-loaded cores.
Multiparticulates are technically more complex than conventional tablets. They also require specialized fluid-bed coating and product-characterization capabilities, which increases the importance of supplier technical support.
Lifecycle management and reformulation
Pharmaceutical companies use extended-release formulations to differentiate products, extend brand value, develop line extensions, or improve adherence. Although the polymer itself is established, a new formulation can generate product-specific intellectual property covering coating architecture, particle size, polymer ratios, manufacturing conditions, and dissolution performance.
This expands demand beyond generic substitution. The same excipient can be purchased for branded reformulations, combination products, and new dosage forms.
Contract manufacturing and development
CDMOs and contract coating specialists purchase functional excipients for multiple client programs. Their buying patterns can create volume leverage but also increase price sensitivity. A CDMO may qualify more than one supplier where the formulation permits substitution, reducing the supplier’s long-term pricing power.
What is the financial trajectory for this excipient?
The most likely financial trajectory is stable specialty-material revenue with moderate growth potential, rather than high-growth pharmaceutical-product economics.
| Financial factor |
Likely effect |
| Increased modified-release development |
Positive volume effect |
| Generic formulation activity |
Positive but price-sensitive |
| Established supplier qualification |
Supports retention and pricing |
| Polymer and energy costs |
Margin pressure |
| Supplier substitution |
Limits price increases |
| Long product-development cycles |
Delays revenue conversion |
| Low dose or coating-use quantities |
Limits absolute market size |
| Regulatory familiarity |
Reduces abandonment risk |
Evonik’s public reporting places EUDRAGIT within broader health-care, nutrition, or specialty-material activities rather than reporting the product line as a standalone business. As a result, no verified public series exists for EUDRAGIT RS revenue, EBITDA, market share, or annual volume.[2]
The economic profile has four stages:
- Development stage: low volume, high technical support requirements, and uncertain commercial conversion.
- Registration stage: qualification and process validation create switching costs.
- Commercial launch stage: recurring orders begin, but volumes depend on product uptake.
- Mature stage: demand is stable and predictable, with pricing influenced by competing polymers and approved-supplier requirements.
The strongest financial characteristic is recurring demand from approved commercial products. The main limitation is that polymer consumption per finished-dose unit is relatively small. A successful pharmaceutical product may generate dependable excipient purchases without making the excipient supplier’s overall financial performance material at corporate scale.
How strong is the competitive position of ammonio methacrylate copolymer type B?
The competitive position is strong in established formulations but weaker in new development programs where developers can select alternative polymers.
Advantages
- Longstanding pharmaceutical use
- Broad formulation literature and technical precedent
- Availability in aqueous and dry forms
- Compatibility with multiparticulate systems
- Adjustable release through coating thickness and polymer blends
- Familiarity among generic and contract-development laboratories
- Established quality and regulatory documentation
Constraints
- Alternative polymers can produce similar release profiles
- Release performance depends heavily on process conditions
- Formulators must manage curing, plasticization, tack, and mechanical strength
- Aqueous dispersions can create storage and processing requirements
- Organic-solvent grades face environmental and manufacturing constraints
- Substitution may be possible during development, although difficult after regulatory filing
Type B does not have a strong patent barrier in the conventional sense. The polymer chemistry is mature, and the commercial opportunity is protected more by manufacturing quality, regulatory documentation, grade consistency, technical support, and formulation know-how than by composition-of-matter patents.
What formulation patents protect products using ammonio methacrylate copolymer type B?
Patents generally protect the drug product or delivery system, not the excipient as a standalone invention. Relevant claim categories include:
- Defined coating compositions
- Specific ratios of type A and type B acrylic polymers
- Coating weight gain
- Polymer-to-drug ratios
- Plasticizer and anti-tacking-agent combinations
- Multiparticulate particle-size distributions
- pH-independent release profiles
- Abuse-deterrent or dose-dumping-resistant formulations
- Manufacturing and curing conditions
- Specific dissolution profiles
- Combination of immediate-release and extended-release populations
An excipient supplier may hold process, grade, or manufacturing know-how, but the principal patent risk for a pharmaceutical customer usually concerns the final dosage form. A generic developer can often avoid a formulation patent by changing polymer ratios, coating architecture, process conditions, or release-control materials.
What is the FDA regulatory status of ammonio methacrylate copolymer type B?
Ammonio methacrylate copolymer type B is a recognized pharmaceutical excipient used in approved drug products. The FDA Inactive Ingredient Database is the principal public source for assessing prior use in specific routes and dosage forms.[3]
The database does not function as a universal product approval for every use. FDA status depends on the specific inactive ingredient, route of administration, dosage form, and precedent in approved products. A developer must still establish identity, specifications, impurity controls, supplier qualification, compatibility, and manufacturing suitability.
Pharmacopeial status is also important. Compendial monographs and supplier documentation support identity and quality control, but they do not replace product-specific regulatory review. Pharmaceutical companies typically evaluate:
- Monomer and residual-solvent controls
- Molecular-weight distribution
- Quaternary ammonium content
- Viscosity and solid content for dispersions
- Particle size for powder grades
- Microbial quality
- Elemental and extractable impurities
- Batch-to-batch release behavior
Which companies compete with Evonik in this market?
Evonik has the clearest branded position through EUDRAGIT. Competitive pressure comes from suppliers of functionally similar polymers rather than exact chemical copies.
| Company |
Competing platform |
Competitive relevance |
| BASF |
Kollicoat SR 30 D |
Water-insoluble sustained-release coating |
| Colorcon |
Surelease |
Ethylcellulose aqueous dispersion |
| Dow |
Ethylcellulose and cellulose-derivative excipients |
Alternative release-control systems |
| Ashland |
Cellulose and film-coating technologies |
Alternative polymer and coating solutions |
| Roquette and other excipient suppliers |
Modified-release and coating excipients |
Formulation-level competition |
Exact chemical substitution may be limited by formulation performance and regulatory history. Functional substitution is more common. The relevant commercial question is whether a competing polymer can reproduce the required dissolution profile at acceptable coating weight, process yield, stability, and cost.
What generic entry risks affect products using this excipient?
The excipient itself does not create a generic-entry date. Generic entry depends on the reference drug’s patents, regulatory exclusivity, formulation claims, and litigation status.
Ammonio methacrylate copolymer type B can influence generic risk in three ways:
- A generic may use the same excipient but a different coating design.
- A generic may use a competing polymer to avoid a formulation patent.
- A patented release profile may make bioequivalence and design-around work more difficult.
For oral modified-release products, the principal commercial risk is often formulation complexity rather than excipient availability. Developers must demonstrate equivalent release behavior and address potential food effects, alcohol-induced dose dumping, and variability across manufacturing scale.
Paragraph IV litigation may target patents covering the finished dosage form, release mechanism, or method of use. The presence of EUDRAGIT RS in both brand and generic products does not, by itself, establish infringement or a route to market.
How does ammonio methacrylate copolymer type B compare with ethylcellulose?
| Attribute |
Ammonio methacrylate copolymer type B |
Ethylcellulose |
| Primary function |
Controlled-release film |
Water-insoluble barrier film |
| Release mechanism |
Diffusion through ionic acrylic polymer membrane |
Diffusion through cellulose matrix or coating |
| Commercial benchmark |
EUDRAGIT RS |
Surelease and related grades |
| Aqueous options |
Available |
Widely available |
| Formulation flexibility |
Strong control through polymer blending |
Strong control through pore formers and coating design |
| Supplier concentration |
Relatively concentrated |
Broader supplier base |
| Substitution difficulty |
Moderate to high after development |
Moderate to high after development |
| Regulatory precedent |
Established |
Established |
Acrylic and ethylcellulose systems can both produce sustained release, but they are not interchangeable without formulation redevelopment. The choice affects coating permeability, curing, mechanical properties, dissolution sensitivity, and process design.
What is the geographic coverage and supply-chain outlook?
The product is globally relevant because oral modified-release medicines are manufactured in North America, Europe, India, China, Japan, and other regulated pharmaceutical markets. Supply-chain value is concentrated in:
- Polymer synthesis
- Dispersion or powder processing
- Pharmaceutical-grade testing
- Regulatory documentation
- Technical formulation support
- Regional warehousing and supply continuity
Manufacturing barriers are higher than for a basic industrial acrylic polymer. Pharmaceutical customers require controlled raw materials, validated processes, traceability, change-control procedures, and regulatory support. A new supplier must qualify both the polymer and the manufacturing site.
The main supply risks are raw-material volatility, plant interruptions, regulatory changes, transport restrictions for dispersions, and customer reluctance to requalify an alternative grade. These factors support incumbent suppliers, although they can also encourage dual sourcing.
Key Takeaways
- Ammonio methacrylate copolymer type B is a mature, specialized excipient used mainly for sustained-release coatings.
- EUDRAGIT RS is the principal commercial reference, with RS 30 D and RS PO representing important product formats.
- Standalone market size, revenue, margin, and market-share data are not publicly reported.
- The financial trajectory is likely stable to moderately growing, driven by modified-release generics, branded lifecycle products, multiparticulates, and CDMO activity.
- The strongest barriers are supplier qualification, regulatory documentation, grade consistency, and formulation know-how.
- Patent exposure generally attaches to the finished dosage form, release architecture, manufacturing process, or method of use rather than to the mature polymer itself.
- Functional alternatives include BASF Kollicoat SR 30 D and ethylcellulose systems such as Colorcon Surelease.
- Generic-entry risk depends on the reference drug’s patents and bioequivalence requirements, not on the presence of ammonio methacrylate copolymer type B alone.
FAQs
Is ammonio methacrylate copolymer type B the same as EUDRAGIT RS?
It is the compendial polymer category associated with EUDRAGIT RS grades. Commercial identity, grade, physical form, and specification must still be confirmed for each supplier and product.
Is ammonio methacrylate copolymer type B biodegradable?
It is a synthetic acrylic copolymer designed for pharmaceutical coating applications. It should not be treated as a biodegradable polymer without product-specific evidence.
Can ammonio methacrylate copolymer type B be used in immediate-release tablets?
It is technically possible as a coating or processing aid, but its primary commercial purpose is controlled release. Its use in an immediate-release product would require a product-specific justification and performance assessment.
Does ammonio methacrylate copolymer type B require an enteric coating?
No. Type B is primarily a sustained-release, water-insoluble polymer. An enteric function generally requires an enteric polymer or a separate pH-dependent coating architecture.
Is EUDRAGIT RS protected by active patents?
The polymer chemistry is mature. Current commercial protection is more likely to depend on manufacturing know-how, trademarks, specifications, technical documentation, and product-specific formulation patents than on a broad, enforceable composition patent covering the basic polymer.
References
-
Evonik Industries AG. (n.d.). EUDRAGIT functional polymers: Product information and technical literature. Evonik Health Care.
-
Evonik Industries AG. (2024). Annual report 2023. Evonik Industries AG.
-
U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. FDA.
-
BASF SE. (n.d.). Kollicoat SR 30 D: Technical information for sustained-release coatings. BASF.
-
Colorcon, Inc. (n.d.). Surelease aqueous ethylcellulose dispersion: Technical product information. Colorcon.
